[LIVE] From Daewon Pharmaceutical's Jincheon Plant
[LIVE] From Daewon Pharmaceutical's Jincheon Plant
  • Cho Pil Hyun, Staff Reporter
  • 승인 2023.09.20 20:27
  • 수정 2023.09.20 20:27
  • 댓글 0
이 기사를 공유합니다

80 billion won invested and completed in 2019 - total area of 18,000 cm2 
6 lines simultaneous manufacturing 42 tons of liquid medicine..."The largest single factory"
"Preparing for the fall seasonal flu, full operation of the factory"
Daewon Pharmaceutical's Jincheon plant, which was completed in 2019 with an investment of more than 80 billion won, covers a total area of approximately 18,000 square meters (about 5,500 pyeong). [Photo courtesy of Daewon Pharmaceutical]
Daewon Pharmaceutical's Jincheon plant, which was completed in 2019 with an investment of more than 80 billion won, covers a total area of approximately 18,000 square meters (about 5,500 pyeong). [Photo courtesy of Daewon Pharmaceutical]

Daewon Pharmaceutical is operating its Jincheon plant at full capacity in preparation for the flu season in the fall.

The company plans to ensure that there is no shortage of seasonal flu medicines.

The Jincheon plant was completed in 2019 by Daewon Pharmaceutical with an investment of more than 80 billion won and occupies a total area of about 18,000 square meters (approximately 5,500 pyeong).

It is the largest single plant for oral liquid medication in Korea.

The Jincheon plant is composed of 6 lines, which can simultaneously manufacture 42 tons of oral liquid medication.

When converted to stick-type pouches, this amounts to 2.856 million pouches per day and 560 million pouches per year.

The plant was designed to be fully automated from the outset, eliminating any contamination of the drug by outside air, from the input of raw materials, through the manufacturing of oral liquids, to the subdivision into disposable pouches.

After manufacturing, the robots automatically transport the boxes to the 42-meter high warehouse and at the time of shipping, the robots automatically recognize the location of products, eliminating the need for human hands.

Daewon Pharmaceutical has recently been operating all of its facilities at full capacity on a two-shift basis to prepare for the onset of respiratory diseases during the season.

A representative from the company said, "We are paying more attention to the production of Codaewon S Syrup, which has an additional indication for infections, and Coldaewon Kids Pen Syrup, which recently resumed production after improving its formulation. We are making sure that there is no supply shortage of cold medicines and expectorants."

[WIKI KOREA=Cho Pil Hyun, Staff Reporter]

chop23@wikileaks-kr.org


  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2024 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 : laputa813@wikileaks-kr.org
ND소프트